NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT04930783 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
Metastatic Melanoma

Interventions

DRUG: CDX-301
BIOLOGICAL: NEOVAX
DRUG: Nivolumab
DRUG: Pembrolizumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]